A retrospective observational study of monotherapy outcomes on the efficacy of third-line or later treatment for patients with HER2 positive unresectable recurrent or metastatic gastric cancer previously treated with trastuzumab

A retrospective observational study of monotherapy outcomes on the efficacy of third-line or later treatment for patients with HER2 positive unresectable recurrent or metastatic gastric cancer previously treated with trastuzumab - A retrospective observational study of monotherapy outcomes on the efficacy of third-line or later treatment for patients with HER2 positive unresectable recurrent or metastatic gastric cancer previously treated with trastuzumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040853

Enrollment

100

Registered

2020-07-01

Start date

2020-08-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive unresectable recurrent or metastatic gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age 20 years or older, at the start of administration 2) Patients diagnosed as HER2 positive gastric cancer by pathological examination in their charts 3) Patients diagnosed with unresectable advanced or recurrent gastric cancer 4) Patients previously treated with T-mab 5) Patients who have started treatment with either Nivo, CPT-11 or FTD/TPI as a single agent in the third-line or later treatment between September 22, 2017 (date to be approved the expanded indication of Nivo for gastric cancer in Japan) and March 31, 2020.

Exclusion criteria

Exclusion criteria: 1) Patients who declined this study before database lock

Design outcomes

Primary

Measure	Time frame
Overall survival, Real world, Progression-free survival, Duration of response, Time to treatment failure, Objective response rate, Disease control rate	—

Countries

Japan

Contacts

Public ContactDaisuke Sakai

Graduate school of Medicine OSAKA University Department of Frontier Science for Cancer and Chemotherapy

dsakai@cfs.med.osaka-u.ac.jp06-6210-8318

Outcome results